DK3781200T3 - Antistoffer for chelaterede radionuklider - Google Patents
Antistoffer for chelaterede radionuklider Download PDFInfo
- Publication number
- DK3781200T3 DK3781200T3 DK19723014.7T DK19723014T DK3781200T3 DK 3781200 T3 DK3781200 T3 DK 3781200T3 DK 19723014 T DK19723014 T DK 19723014T DK 3781200 T3 DK3781200 T3 DK 3781200T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- chelated radionuclides
- chelated
- radionuclides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Detergent Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658468P | 2018-04-16 | 2018-04-16 | |
| PCT/EP2019/059856 WO2019201959A1 (en) | 2018-04-16 | 2019-04-16 | Antibodies for chelated radionuclides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3781200T3 true DK3781200T3 (da) | 2024-08-05 |
Family
ID=66476592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19723014.7T DK3781200T3 (da) | 2018-04-16 | 2019-04-16 | Antistoffer for chelaterede radionuklider |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220389116A1 (da) |
| EP (2) | EP4406607A2 (da) |
| JP (2) | JP7475283B2 (da) |
| KR (1) | KR20210005885A (da) |
| CN (1) | CN112261952A (da) |
| AR (1) | AR115053A1 (da) |
| AU (1) | AU2019254537A1 (da) |
| BR (1) | BR112020021061A2 (da) |
| CA (1) | CA3096338A1 (da) |
| CL (1) | CL2020002680A1 (da) |
| CR (1) | CR20200548A (da) |
| DK (1) | DK3781200T3 (da) |
| FI (1) | FI3781200T3 (da) |
| IL (1) | IL277575A (da) |
| LT (1) | LT3781200T (da) |
| MA (1) | MA52545A (da) |
| MX (1) | MX2020010954A (da) |
| PE (1) | PE20210442A1 (da) |
| PT (1) | PT3781200T (da) |
| RS (1) | RS65753B1 (da) |
| SG (1) | SG11202010066TA (da) |
| TW (1) | TW202011987A (da) |
| WO (1) | WO2019201959A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4178985A1 (en) | 2020-07-10 | 2023-05-17 | F. Hoffmann-La Roche AG | Antibodies which bind to cancer cells and target radionuclides to said cells |
| AU2022207615A1 (en) | 2021-01-12 | 2023-07-13 | F. Hoffmann-La Roche Ag | Split antibodies which bind to cancer cells and target radionuclides to said cells |
| JP2024503654A (ja) | 2021-01-13 | 2024-01-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 併用療法 |
| CA3238399A1 (en) | 2021-12-15 | 2023-06-22 | Torben LUND-HANSEN | Scfv and antibodies with reduced multimerisation |
| WO2024099526A1 (en) | 2022-11-08 | 2024-05-16 | Y-Mabs Therapeutics, Inc. | Bispecific antibody compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3236988B8 (en) | 2014-12-23 | 2020-08-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of bacterial superinfections post-influenza |
| WO2016130539A2 (en) * | 2015-02-09 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof |
| EP3243836A1 (en) * | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
| JP2021521245A (ja) | 2018-04-16 | 2021-08-26 | オラノ メド エスアエス | キレート化された放射性核種に対する抗体および除去剤 |
-
2019
- 2019-04-16 MA MA052545A patent/MA52545A/fr unknown
- 2019-04-16 JP JP2020556869A patent/JP7475283B2/ja active Active
- 2019-04-16 PT PT197230147T patent/PT3781200T/pt unknown
- 2019-04-16 AR ARP190101005A patent/AR115053A1/es unknown
- 2019-04-16 PE PE2020001551A patent/PE20210442A1/es unknown
- 2019-04-16 CA CA3096338A patent/CA3096338A1/en active Pending
- 2019-04-16 US US17/048,073 patent/US20220389116A1/en active Pending
- 2019-04-16 SG SG11202010066TA patent/SG11202010066TA/en unknown
- 2019-04-16 AU AU2019254537A patent/AU2019254537A1/en active Pending
- 2019-04-16 FI FIEP19723014.7T patent/FI3781200T3/fi active
- 2019-04-16 DK DK19723014.7T patent/DK3781200T3/da active
- 2019-04-16 MX MX2020010954A patent/MX2020010954A/es unknown
- 2019-04-16 EP EP24169799.4A patent/EP4406607A2/en active Pending
- 2019-04-16 LT LTEPPCT/EP2019/059856T patent/LT3781200T/lt unknown
- 2019-04-16 RS RS20240810A patent/RS65753B1/sr unknown
- 2019-04-16 TW TW108113285A patent/TW202011987A/zh unknown
- 2019-04-16 BR BR112020021061-7A patent/BR112020021061A2/pt unknown
- 2019-04-16 CR CR20200548A patent/CR20200548A/es unknown
- 2019-04-16 KR KR1020207032824A patent/KR20210005885A/ko active Search and Examination
- 2019-04-16 WO PCT/EP2019/059856 patent/WO2019201959A1/en active Application Filing
- 2019-04-16 CN CN201980038709.1A patent/CN112261952A/zh active Pending
- 2019-04-16 EP EP19723014.7A patent/EP3781200B1/en active Active
-
2020
- 2020-09-24 IL IL277575A patent/IL277575A/en unknown
- 2020-10-16 CL CL2020002680A patent/CL2020002680A1/es unknown
-
2024
- 2024-01-12 JP JP2024003062A patent/JP2024056687A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024056687A (ja) | 2024-04-23 |
| PT3781200T (pt) | 2024-07-19 |
| MA52545A (fr) | 2021-02-24 |
| TW202011987A (zh) | 2020-04-01 |
| FI3781200T3 (fi) | 2024-07-31 |
| LT3781200T (lt) | 2024-08-12 |
| EP3781200A1 (en) | 2021-02-24 |
| PE20210442A1 (es) | 2021-03-08 |
| RS65753B1 (sr) | 2024-08-30 |
| EP3781200B1 (en) | 2024-05-29 |
| SG11202010066TA (en) | 2020-11-27 |
| CN112261952A (zh) | 2021-01-22 |
| CR20200548A (es) | 2021-01-20 |
| AR115053A1 (es) | 2020-11-25 |
| CA3096338A1 (en) | 2019-10-24 |
| WO2019201959A1 (en) | 2019-10-24 |
| MX2020010954A (es) | 2020-11-09 |
| JP7475283B2 (ja) | 2024-04-26 |
| AU2019254537A1 (en) | 2020-10-29 |
| IL277575A (en) | 2020-11-30 |
| JP2021520832A (ja) | 2021-08-26 |
| BR112020021061A2 (pt) | 2021-02-17 |
| KR20210005885A (ko) | 2021-01-15 |
| US20220389116A1 (en) | 2022-12-08 |
| EP4406607A2 (en) | 2024-07-31 |
| CL2020002680A1 (es) | 2021-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279321A (en) | Anti-SIRPalpha antibody | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
| MA53434A (fr) | Anticorps anti-tigit | |
| MA52884A (fr) | Anticorps anti-il-11 | |
| IL280013A (en) | Anti-IL36R antibodies | |
| IL279352A (en) | IL-11RA antibodies | |
| DK3781200T3 (da) | Antistoffer for chelaterede radionuklider | |
| IL278010A (en) | Antibodies to galectin 10 | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| IL277030A (en) | Antibodies | |
| MA52366A (fr) | Anticorps anti-tl1a optimisés | |
| SG11202106171WA (en) | Anti-btla antibodies | |
| ZA202101177B (en) | Anti-btla antibody | |
| GB201811368D0 (en) | Antibody | |
| IL281594A (en) | Antibodies against KLRG1 | |
| GB201817172D0 (en) | Antibody | |
| GB201806084D0 (en) | Antibodies | |
| PL3671200T3 (pl) | Zastosowania ce-western do opracowywania przeciwciał | |
| ES1210164Y (es) | Abonadora | |
| SG11202105718TA (en) | Modified antibodies | |
| GB201817188D0 (en) | Antibody library | |
| GB201813597D0 (en) | Antibody | |
| GB201819952D0 (en) | Antibodies | |
| GB201809945D0 (en) | Antibody |